Deals this week: Adaptive Biotechnologies, Neurent Medical

1 June 2018 (Last Updated November 22nd, 2018 11:23)

Adaptive Biotechnologies has announced it will use Sanofi's clonoSEQ® assay to measure minimal residual disease (MRD) in multiple myeloma patients treated with isatuximab.

Adaptive Biotechnologies has announced Sanofi will use its clonoSEQ® assay to measure minimal residual disease (MRD) in multiple myeloma patients treated with isatuximab.

Adaptive will be responsible for the commercialisation and for seeking regulatory approvals of the clonoSEQ assay, as part of the agreement.

Based in the US, Adaptive is a medical device company engaged in combining next-generation sequencing (NGS) and bioinformatics to profile T-cell and B-cell receptors, while Sanofi, based in France, is a biopharmaceutical company focused on human health.

The agreement enables both the companies to evaluate the clinical value of monitoring MRD in multiple myeloma (MM) trials involving isatuximab.

Neurent Medical Limited has raised €9.3m ($11m) through a series A financing round provided by Fountain Healthcare Partners.

The funding also involved the participation of Atlantic Bridge Capital, the Western Development Commission, Enterprise Ireland, as well as a syndicate of Irish and US medical device veterans.

Based in the US, Neurent Medical is a developer of a medical device for treating rhinitis. All the investors involved in the transaction are based in Ireland.

“ePatientFinder’s technology platform will enable Elligo to automate its electronic health record (EHR) data analytics capabilities and expand its technology.”

The funding will be used towards the development and launch of the device in the US.

The Straumann Group (Straumann Holding AG) has signed an agreement to collaborate with Zirkonzahn USA Inc.

The partnership will include co-development and co-marketing activities in the US and Canada for dental clinicians and technicians.

Based in Switzerland, Straumann specialises in tooth replacement and orthodontic solutions, while Zirkonzahn is a US-based dental device company.

The collaboration enables both the companies to use seamless digital workflow that ensures patient satisfaction.

CardiacSense Ltd has raised $0.5m through a private placement of shares of its common stock.

The placement was subscribed to by Merchavia Holdings and Investments Ltd.

Based in Israel, CardiacSense is a developer of innovative optical-base non-invasive technology for monitoring blood parameters.

Mobidiag Ltd has raised €4m ($4.68m) through a venture financing round led by Springvest Oy.

Based in Finland, Mobidiag develops and provides easy-to-use solutions for in-vitro diagnostics of infectious diseases.

The company plans to use the funds to expand the production of its Novodiag instruments and fortify its global sales and marketing activities.

Teleflex Inc and Teleflex Life Sciences Unlimited Company will acquire QT Vascular Ltd’s non-drug-coated product line.

Teleflex will make a cash payment of S$98.4m ($73.24m), including S$26.2m ($19.5m) for the non-coated coronary products, S$65.6m ($48.83m) for the coated coronary products and up to S$6.6m ($4.91m) upon achieving certain sales milestones.

Based in the US, Teleflex is a medical device company, while QT Vascular is a Singapore-based company involved in the development of minimally invasive medical devices for the treatment of vascular disease.

The transaction enables Teleflex to develop and market its other products.

Elligo Health Research (Eligo) has completed the acquisition of ePatientFinder’s clinical trial exchange technology platform.

ePatientFinder’s technology platform will enable Elligo to automate its electronic health record (EHR) data analytics capabilities and expand its technology to further benefit physicians, patients and sponsors.

Elligo is involved in the development of a technology platform aimed at enhancing clinical trial access and advancing the development of medical device products and therapies, while ePatientFinder is a healthcare technology company.

Both the companies involved in the transaction are based in the US.